

11 May 2023

**Diaceutics PLC**  
("Diaceutics" or "the Company")

**PDMR shareholdings**

Diaceutics PLC, (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, has been informed that Jordan Clark, Chief Commercial Officer, a Person Discharging Managerial Responsibilities ('PDMR'), has on 4 May 2023 sold 50,000 Ordinary Shares in the Company each, at a price of 98 pence per Ordinary Share. This is the last sale in a tranche of shares currently being sold by Jordan Clark.

**Enquiries:**

**Diaceutics PLC**  
Peter Keeling, Chief Executive Officer  
Nick Roberts, Chief Financial Officer  
Via Alma PR

**Stifel Nicolaus Europe Limited (Nomad & Broker)**  
Ben Maddison  
Nick Harland  
Nick Adams  
Tel: +44 (0)20 7710 7600

**Alma PR**  
Caroline Forde  
Kieran Breheny  
Matthew Young  
Kinvara Verdon  
Tel: +44(0)20 3405 0205  
diaceutics@almapr.co.uk

**About Diaceutics**

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>		
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>		
a.	Name	Jordan Clark
<b>2 Reason for notification</b>		
a.	Position/Status	Chief Commercial Officer

b.	Initial notification/ Amendment	Initial				
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a.	Description of the financial instrument, type of instrument  Identification Code	Ordinary shares of £ 0.002 each  ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Sale of Ordinary Shares				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>98 pence</td> <td>50,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	98 pence	50,000
Price(s)	Volume(s)					
98 pence	50,000					
d.	Date of the transaction	4 May 2023				
e.	Place of the transaction	AIM Market of the London Stock Exchange				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSFAFWFEDSEFI